Clik here to view.
What the meltdown in the stock market means for biotech and pharma
On Monday, global market indices crashed after a week of soft corporate earnings, a macroeconomic warning, and concerns that the Federal Reserve had waited too long to cut interest rates. Biotech and...
View ArticleThird Rock and Arie Belldegrun’s firm come together for CD20/CD3 bispecific...
Another CD20/CD3 bispecific is entering the fold, except this time for autoimmune diseases. Prolific biotech creator Third Rock Ventures and Arie Belldegrun’s Two River have joined forces to create a...
View ArticleQ&A: Genentech’s new CEO says AI is not coming for company scientists and the...
Genentech and Roche are pretty much the only two companies that Ashley Magargee knows. The biopharma veteran has spent two decades at both (including before their 2009 merger) and took over as...
View ArticleBristol Myers to cut more jobs at headquarters as part of announced restructure
Roughly two months after Bristol Myers Squibb disclosed hundreds of job cuts at its New Jersey corporate headquarters, it’s further shrinking the headcount there. Another 117 layoffs are coming to the...
View ArticleMallinckrodt sells photopheresis platform Therakos for $925M
Less than a year after emerging from its second bankruptcy, Mallinckrodt is selling its photopheresis platform Therakos to help pay off debt. Luxembourg-based CVC Capital Partners has agreed to pay...
View ArticleNuvation pauses BET inhibitor plans after checking out interim Phase 1 data
Nuvation Bio won’t take its cancer drug NUV-868 into a Phase 2 trial for now, following a look at interim safety and efficacy data from a Phase 1 trial. The disclosure came in the biotech’s...
View ArticleEliot Forster’s pain biotech unveils Phase 2 data in degenerative joint disease
UK biotech Levicept said its first-in-class biologic can help ease pain and stiffness in patients with moderate to severe osteoarthritis, according to mid-stage data released Tuesday. The Phase 2...
View ArticleClik here to view.
BioMarin scales back launch for hemophilia gene therapy, pitches path to...
BioMarin Pharmaceutical is reeling in its gene therapy ambitions. On Monday, the company announced that it’s lowering spending plans for its hemophilia gene therapy, Roctavian, and stopping development...
View ArticleExclusive: Biotech investor Sofinnova hires former Biogen medical chief
Maha Radhakrishnan, who left her post as chief medical officer at Biogen earlier this year, is now an executive partner at Sofinnova Investments, the firm exclusively told Endpoints News. Radhakrishnan...
View ArticleClik here to view.
Ultimovacs’ cancer vaccine UV1 flunks Phase 2 head and neck cancer trial
For a second time this year, Ultimovacs saw its stock crash after reporting its cancer vaccine failed in a Phase 2 study in head and neck squamous cell carcinoma. Topline data from the Phase 2 FOCUS...
View ArticleBayer details 3,200 job cuts so far, spotlights ‘momentum’ in pharma pipeline
Bayer is “on track” to realize the €2 billion in cost savings it’s aiming for in 2026, executives say, even as they report another quarter of “modest” performance across its crop science,...
View ArticleA new Apple Tree Partners biotech launches with $55M to make ‘pan-variant’...
Red Queen Therapeutics is emerging from stealth with $55 million from venture capital group Apple Tree Partners, and plans to develop treatments for a swathe of viral infections including Covid-19 and...
View ArticleClik here to view.
Merck enlists partner Daiichi Sankyo to develop T cell engager from Harpoon...
Daiichi Sankyo is paying Merck $170 million upfront to snag joint development and commercialization rights to a Phase 1/2 T cell engager that the New Jersey pharma giant got in its Harpoon acquisition...
View ArticleClik here to view.
Exclusive: TCG, DCVC and Lux back new autoimmune biotech from Kallyope...
A stealth biotech from repeat collaborators has assembled the latest industry megaround. New York-based NILO Therapeutics has put together a $101 million Series A, Tim Kutzkey, a board member and...
View ArticleGenentech partners with cash-strapped Sangamo on epigenetic Alzheimer’s therapy
An experimental Alzheimer’s drug and its designer are getting a second chance. On Tuesday, Sangamo announced it had partnered with Genentech to develop an epigenetic repressor to prevent the production...
View ArticleClik here to view.
Hims takes steps to lock up drug supply for its booming weight loss business
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Hims CEO Andrew Dudum did his best Monday to reassure investors that the digital health startup’s...
View ArticleArie Belldegrun and team unveil $600M life sciences credit firm amid...
A new $600-plus million credit firm was unveiled Tuesday morning from Arie Belldegrun and other well-known life sciences names. Rather than create another venture capital firm, the Kite Pharma founder...
View ArticleClik here to view.
Exclusive: Covid and epidemic threat biotech Aerium Therapeutics closes after...
Aerium Therapeutics has ceased operations, ending its mission to bring to market new antibodies to protect immunocompromised people from Covid-19, develop highly sought-after long Covid treatments and...
View ArticleBioCryst culls Factor D inhibitor; Elevation Oncology’s stock plummets
Plus, news about Tenax Therapeutics: BioCryst discontinues Factor D inhibitor: This is after finding that “clinical activity observed was less than other therapies on the market.” The company tried to...
View ArticleClik here to view.
Eisai picks SEED Therapeutics for molecular glue deal worth as much as $1.5B
Eisai is paying SEED Therapeutics an undisclosed amount upfront in a deal worth up to $1.5 billion to develop new ‘molecular glue’-based therapies for neurodegenerative diseases and cancer. The...
View Article